sulfur hexafluoride lipid-type a microspheres
Trade name: Lumason
Small moleculeapprovedImaging agent
Approved
Oct 10, 2014
SULFUR HEXAFLUORIDE is a component of LUMASON® (sulfur hexafluoride lipid-type A microspheres). It is an ultrasound contrast agent indicated for use in the heart echocardiography and in ultrasonography of the liver and the urinary tract. The sulfur hexafluoride lipid microspheres are composed of SF6 gas in the core surrounded by an outer shell monolayer of phospholipids with palmitic acid as a stabilizer. — NCATS
Clinical trial activity
61 trials · 42 clinical orgs · 1 marketing orgs
Phase 1
15
Phase 2
34
Phase 3
22
Phase 4
7
Earliest trial started Sep 1, 1985 (NCT00000140)
Timeline
Indications
Approved for
Studied for
- Abdominal Injuries · Phase 4
- Accidental Falls · Phase 4
- Acute Febrile Encephalopathy · Phase 3
- Alzheimer Disease · Phase 1
- Appendicitis · Phase 2
- Brain Diseases · Phase 3
- Brain Neoplasms · Phase 3
- Breast Neoplasms · Phase 3
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Pancreatic Ductal · Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Coronary Artery Disease · Phase 3
- COVID-19 · Phase 3
- Crohn Disease · Phase 4
- Developmental Dysplasia of the Hip · Early Phase 1
- Enterocolitis, Necrotizing · Phase 3
- Eye Diseases · Phase 3
- Fetal Growth Retardation · Phase 3
- Fibrosis · Phase 3
- Glioblastoma · Phase 3
- Glioma · Phase 3
- Heart Diseases · Phase 3
- Hemorrhage · Phase 4
- Hereditary Autoinflammatory Diseases · Phase 3
- Hydrocephalus · Phase 2
- Hypertension, Pulmonary · Phase 2
- Hypoxia-Ischemia, Brain · Phase 3
- Infant, Premature, Diseases · Phase 3
- Intestinal Diseases · Phase 3
- Ischemic Stroke · Phase 3
- Kidney Transplantation · Phase 1
- Liver Diseases · Phase 4
- Liver Neoplasms · Phase 3
- Lung Diseases · Phase 1/Phase 2
- Lymphedema · Phase 1
- Mitochondrial Diseases · Phase 1
- Mitochondrial Myopathies · Phase 1
- Motor Vehicles · Phase 4
- Neoplasm Metastasis · Phase 4
- Neoplasms · Phase 3
- Neoplasms, Nerve Tissue · Phase 3
- Ovarian Torsion · Phase 3
- Physical Abuse · Phase 4
- Pregnancy · Phase 3
- Prostatic Neoplasms · Phase 3
- Retinal Detachment · Phase 3
- Stroke · Phase 3
- Systemic Inflammatory Response Syndrome · Phase 3
- Tetralogy of Fallot · Phase 1/Phase 2
- Traumatology · Phase 4
- Ultrasonography · Early Phase 1
- Urinary Tract Infections · Phase 2
- Vesico-Ureteral Reflux · Phase 4
- Vitreoretinopathy, Proliferative · Phase 3
- Wet Macular Degeneration · Phase 3
Mechanism of action
- Unspecified targetOTHER
Diagnostic agent
- contrast mediumRadiopaque
contrast medium radiopaque
Approval history
- approvedOct 10, 2014
Chemistry & pharmacology
Loading structure…
SMILES
FS(F)(F)(F)(F)F- Mol. weight
- 146.055 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Black box warning
Sources
- NCATSWS7LR3I1D6 ↗
- ChEMBLCHEMBL3545306 ↗
- ChEMBLCHEMBL1796998 ↗
Also known as
- bri
- bri
- contrast agent br1
- hexafluoridosulfur
- hexafluoridosulfur
- hexafluorosulfur
- lumason
- lumason
- sf2 compound
- sonovue
- sonovue
- sonovue
- sonovue
- sonovue
- sonovue
- sonovue
- sonovue (for the microbubble formulation)
- sonovue (for the microbubble formulation)
- sulfur(6+) fluoride
- sulfur(6+) fluoride
- sulfur difluoride
- sulfur fluoride
- sulfur fluoride
- sulfur fluoride
- sulfur fluoride
- sulfur hexafluoride
- sulfur hexafluoride
- sulfur hexafluoride
- sulfur hexafluoride
- sulfur hexafluoride
- sulfur hexafluoride
- sulfur hexafluoride lipid microsphere
- sulfur hexafluoride lipid microsphere
- sulfur hexafluoride lipid microsphere
- sulfur hexafluoride lipid-type a microspheres
- sulfur hexafluoride lipid-type a microspheres
- sulfur hexafluoride lipid-type a microspheres
- sulfur hexafluoride lipid-type a microspheres
- sulfur(vi) fluoride
- sulfur(vi) fluoride
- sulphur hexafluoride
- sulphur hexafluoride
- sulphur hexafluoride
- sulphur hexafluoride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07274787 | N/A | Jan 1, 2026 | NaviFUS Corporation, University of Cincinnati |
| NCT06677554 | Phase 3 | Jan 1, 2025 | University of Lorraine |
| NCT06693752 | Phase 2 | Nov 14, 2024 | University of Pennsylvania |
| NCT06600880 | Phase 1 | Oct 1, 2024 | Columbia University |
| NCT06497959 | Phase 3 | Sep 2, 2024 | University of Lorraine |
| NCT06496971 | Phase 3 | Sep 1, 2024 | NaviFUS Corporation |
| NCT06329570 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2024 | NaviFUS Corporation |
| NCT06400004 | Phase 3 | Apr 30, 2024 | Bracco |
| NCT05957042 | Early Phase 1 (Phase 1) | Sep 1, 2023 | Pennsylvania State University |
| NCT05694611 | Phase 3 | May 31, 2023 | University of Turku |
| NCT05648812 | Phase 3 | Jan 31, 2023 | University of Turku |
| NCT05613946 | Phase 1 | Dec 15, 2022 | Mayo Clinic |
| NCT05569122 | Phase 1 | Nov 30, 2022 | Chang Gung University, Department of Defense, University of Pennsylvania |
| NCT05186415 | Phase 1/Phase 2 (Phase 2) | Aug 23, 2022 | Nemours Children's Health System, Thomas Jefferson University |
| NCT04718441 | Phase 1/Phase 2 (Phase 2) | May 10, 2021 | Harvard University |
| NCT04663750 | Phase 3 | Dec 31, 2020 | University of London |
| NCT04640038 | Phase 3 | Dec 31, 2020 | University of Pennsylvania |
| NCT04569799 | N/A | Oct 14, 2020 | Pennsylvania State University |
| NCT04146441 | Phase 2 | Jan 31, 2020 | Norwegian University of Science and Technology |
| NCT03821376 | Phase 4 | Jul 16, 2019 | Indiana University |
Showing 20 of 61 trials
Page 1 / 4
Organizations
Research & Development (42)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bracco | For profit | 9 | 8 | 3 | 2009 |
| University of Pennsylvania | Academic/Hospital | 8 | 8 | 4 | 2017 |
| Harvard University | Academic/Hospital | 4 | 4 | 3 | 2017 |
| Mayo Clinic | Academic/Hospital | 3 | 3 | 2 | 2017 |
| NaviFUS Corporation | For profit | 3 | 2 | 3 | 2024 |
| University of Lorraine | Academic/Hospital | 3 | 3 | 1 | 2016 |
| François Rabelais University | Academic/Hospital | 2 | 0 | 1 | 2004 |
| Indiana University | Academic/Hospital | 2 | 2 | 1 | 2016 |
| Norwegian University of Science and Technology | Academic/Hospital | 2 | 2 | 1 | 2018 |
| Pennsylvania State University | Academic/Hospital | 2 | 2 | 2 | 2020 |
| University of Amsterdam | Academic/Hospital | 2 | 2 | 1 | 2011 |
| University of Turku | Academic/Hospital | 2 | 2 | 1 | 2023 |
| American Heart Association | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Chang Gung University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Columbia University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Department of Defense | Government | 1 | 0 | 1 | 2022 |
| Emek Medical Center | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Free University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2017 |
| General Electric | For profit | 1 | 1 | 1 | 2014 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2017 |
42 organizations
Page 1 / 3